Skip to main content

Stephenson Brian C's Form 4 filing

BridgeBio Pharma, Inc. (BBIO) · filed Feb 19, 2025

Accession no.
0000950170-25-023630
Filed
Feb 19, 2025
Trade date
Feb 16-19, 2025
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 4 derivative transactions. Open-market sales total $150.0K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Stephenson Brian CCIK 0001780030Officer (Secretary, Treasurer & CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 16, 2025Common StockMOption exerciseAcquired+25,798–F1–119,714Direct
Feb 16, 2025Common StockFTax withholdingDisposed−13,102$34.90−$457,259.8106,612Direct
Feb 19, 2025Common StockSSaleDisposed−4,148$36.16F5−$149,991.68102,464Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 16, 2025Common StockMOption exerciseDisposed−779$0.00$00Direct
Feb 16, 2025Common StockMOption exerciseDisposed−946$0.00$02,840Direct
Feb 16, 2025Common StockMOption exerciseDisposed−17,368$0.00$0138,947Direct
Feb 16, 2025Common StockMOption exerciseDisposed−6,705$0.00$080,459Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Referenced by the price of 1 transaction in Table I.

F5

Represents the weighted average sale price of the shares sold from $35.57 to $36.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)